Navigation Links
Artemis Health Hires Richard Rava, Ph.D., as Senior Vice President of Research and Development
Date:2/9/2009

MENLO PARK, Calif., Feb. 9 /PRNewswire/ -- Artemis Health Inc., a privately-held company dedicated to the development of non-invasive prenatal diagnostic tests, today announced that Richard Rava, Ph.D., has joined Artemis Health in the newly created position of senior vice president of research and development.

"Rich's depth and breadth of research, development and manufacturing experience, together with his proven track record in commercializing genetic analysis tools, makes him uniquely suited to lead our efforts to bring non-invasive prenatal diagnostic tests to the market," said Lissa Goldenstein, president and chief executive officer of Artemis Health.

Dr. Rava brings more than 20 years of research, development and operational expertise in molecular and genetic analysis for commercial assays and instrumentation. He comes to Artemis after 16 years at Affymetrix where he was a scientific co-founder and most recently senior vice president of research and development. During his tenure, Dr. Rava led the research, development and manufacturing scale-up of the Affymetrix' GeneChip(R) technology. He was responsible for the delivery of multiple products involving complex assays, microarrays, instrumentation and software that applied scientific technology to meet the needs of the gene expression, genetics research and clinical markets.

Prior to co-founding Affymetrix, Dr. Rava served as a senior scientist at Affymax Research Institute. From 1990 through 1992, he served as principal research scientist at the George R. Harrison Spectroscopy Laboratory, Massachusetts Institute of Technology (MIT). During that time, he was also the research coordinator for the National Institute of Health Laser Biomedical Research Center at MIT. Dr. Rava has published over 60 papers in peer-reviewed scientific publications and is an author on over 30 issued U.S. patents. He received his B.A. and Ph.D., in chemistry from Rutgers University.

"Artemis Health is the only company focused exclusively on the development of non-invasive prenatal tests to determine genetic abnormalities using both intact cell and cell-free fetal DNA analysis tools," remarked Dr. Rava. "I am extremely excited to join this highly-committed team, and look forward to playing an active role in the rapidly evolving field of prenatal diagnostics."

The Artemis Advantage for Prenatal Testing

Prenatal testing is an important tool for most pregnancies in the United States and the rest of the developed world. While the results of these tests provide timely information about the well-being of the fetus, it is broadly agreed that a safer prenatal diagnostic test offered early would allow women and their families to make more informed decisions about their pregnancy and better prepare for potential problems in their infants.

Artemis Health is developing non-invasive, genome-based prenatal tests for use in early pregnancy to diagnose genetic abnormalities and chromosomal aneuploidies (abnormal number of chromosomes). Through a single maternal blood draw early in pregnancy, Artemis' diagnostic tests are being designed to isolate intact fetal cells and cell-free fetal DNA to provide valuable and accurate genetic information without risk to the mother or her baby.

About Artemis Health Inc.

Artemis Health Inc. is a privately-held, diagnostics company focused on the development of non-invasive early-pregnancy prenatal tests for use in all pregnant women. Working in collaboration with leading research and clinical institutions, the company has developed cutting-edge technology to transform the field of prenatal testing through the analysis of both whole-cell and cell-free fetal DNA isolated from maternal blood. With a single, maternal blood draw early in pregnancy, Artemis' diagnostic tests are being designed to provide women with an accurate alternative to the invasive methods of amniocentesis and chorionic villus sampling available today. For more information about Artemis Health, please visit http://www.artemishealthinc.com.


'/>"/>
SOURCE Artemis Health Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Exelixis Sells 80% Stake in Artemis to Taconic
2. Artemis Health Licenses Prenatal Cell-Free DNA Analysis Technology from Stanford University
3. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
4. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
5. Healthcare Technologies Calls for a Shareholders Meeting to Approve the Nexgen Biofuels Transaction
6. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
7. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. InterCure and Omron Healthcare (UK) Ltd. Announce Marketing Collaboration for Hypertension Market in United Kingdom
10. Apria Healthcare Chooses Masimo SET Pulse Oximetry for Use in the Companys Home Health Care Business
11. NuVasive to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2016)... ... May 20, 2016 , ... Kablooe Design, a leading provider ... announced its official 25th anniversary of the business. “We have worked hard to build ... our customers for the privilege and honor of serving their product design and development ...
(Date:5/19/2016)... RIDGE, British Columbia , May 19, 2016 ... AdvanTec Global Innovations Inc. (AGI), based out of ... recently added Greenlane Biogas Ltd. to its existing ... 2-year contract manufacturing agreement. AFS along with its ... Technologies (ABT) is a vertically integrated industrial group ...
(Date:5/19/2016)... May 19, 2016 - I ... orale durante il 52 ° ...    - Le conclusioni dello studio indicano ... pazienti trattati, di cui il 90% presenta una d ... o più. Il settantadue per cento dei pazienti ha riscontrato ...
(Date:5/18/2016)... ... 18, 2016 , ... STACS DNA Inc., the sample tracking software company, today ... assault kit processing to help them save time and reduce errors. , Sexual Assault ... be processed and victims informed of results. Due to a previous lack of tools, ...
Breaking Biology Technology:
(Date:3/31/2016)... -- Genomics firm Nabsys has completed a financial  restructuring under ... M.D., who returned to the company in October 2015. ... including Chief Technology Officer, John Oliver , Ph.D., ... Vice President of Software and Informatics, Michael Kaiser ... Bready served as CEO of Nabsys from 2005-2014 and ...
(Date:3/22/2016)... PROVO and SANDY, ... Screening Ontario (NSO), which operates the highest sample volume ... testing, and Tute Genomics and UNIConnect, leaders in clinical ... today announced the launch of a project to establish ... testing panel. NSO has been contracted ...
(Date:3/15/2016)... 15, 2016 --> ... Transparency Market Research "Digital Door Lock Systems Market - Global ... 2023," the global digital door lock systems market in terms ... and is forecast to grow at a CAGR of 31.8% ... and medium enterprises (MSMEs) across the world and high industrial ...
Breaking Biology News(10 mins):